FDA Approves Empliciti, A New Immune-Stimulating Therapy To Treat Multiple Myeloma
(FDA.gov) Nov 30, 2015 - Today the U.S. Food and Drug Administration granted approval for Empliciti (elotuzumab) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications.
read press release »
View ALL News »
Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.
OBR Job Board
Seattle Genetics has 1 job posted.
Check out the OBR Job Board here.